We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A fourth boy has died in Astellas Gene Therapies’ 24-patient ASPIRO study of AT132, an adeno-associated virus vector treatment for myotubular myopathy. Read More
Eli Lilly’s solanezumab, an investigational antibody treatment for Alzheimer’s disease, has been floundering between outright disasters and glimpses of hope since the mid-2000s. It has disappointed in five separate phase 3 studies so far, most recently last year when it flopped in the highly anticipated DIAN-TU study, which found that it exerted no cognitive benefit in patients with dominantly inherited Alzheimer’s disease. Read More
Adding two immune checkpoint inhibitors to platinum-based chemotherapy extended progression-free survival and reduced the risk of death in patients with metastatic small-cell lung cancer, relative to a single blocker/chemo combination or chemotherapy alone. Read More
Apellis Pharmaceuticals said it will proceed with a new drug application (NDA) for an injectable form of Empaveli (pegcetacoplan) for treatment of geographic atrophy (GA), the leading cause of blindness in the elderly, despite conflicting results from two late-stage studies. Read More
Seven vaccines are currently approved by the World Health Organization, but all the stock is bound by contractual agreement that restricts its use to public health measures. Read More
Moderna is working on a new booster vaccine, mRNA-1073, that combines the drugmaker’s COVID-19 shot with its experimental flu vaccine in a single dose. Read More
“We need to fight today’s pandemic but also ensure we are prepared with new drugs to combat viruses with future pandemic potential,” said Exscientia CEO Andrew Hopkins. Read More
Neutralizing antibody activity against Delta was not observed in samples obtained from vaccinated individuals six months following a second dose, the researchers said. Read More
Approved vaccines and the diminishing numbers of unexposed individuals are making placebo-controlled trials for COVID-19 vaccines a thing of the past, so researchers will have to rely on active comparators to develop second-generation shots. Read More